

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Dasatinib for the treatment of acute lymphoblastic leukaemia

Response to consultee and commentator comments on the matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:				
matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	<i>The Leukaemia Society (UK) should be listed as Leukaemia Society (UK) and moved up the list.</i>	PPIP	<i>Noted</i>	

National Institute for Health and Clinical Excellence

Response to comments on the matrix of consultees and commentators for the appraisal of dasatinib for acute lymphoblastic leukaemia

Issue date: July 2008

2.	<i>Please remove Chronic Lymphocytic Leukaemia Support Association (CLLSA) as they focus exclusively on CLL.</i>	PPIP	Removed	<i>This organisation's interests are not related to the appraisal topic. Therefore the CLLSA have been removed from the matrix.</i>
3.	<i>Chronic Myeloid Leukaemia Support Group – they have a few 'hits' on ALL but seem to focus mainly on CML.</i>	PPIP	Removed	<i>This organisation's interests are not related to the appraisal topic. Therefore the Chronic Myeloid Leukaemia Support Group have been removed from the matrix.</i>

National Institute for Health and Clinical Excellence

Response to comments on the matrix of consultees and commentators for the appraisal of dasatinib for acute lymphoblastic leukaemia

Issue date: July 2008